Toggle light / dark theme

Pathogen Mishaps Rise as Regulators Stay Clear

We are being told that mistakes can not happen in labs. I for one do not believe such, so let me take you on a trip down memory lane to 2014, around the same year funding of gain of function was stopped.

Lab workers at different sites accidentally jabbed themselves with needles contaminated by anthrax or West Nile virus. An air-cleaning system meant to filter dangerous microbes out of a lab failed, but no one knew because the alarms had been turned off. A batch of West Nile virus, improperly packed in dry ice, burst open at a Federal Express shipping center. Mice infected with bubonic plague or Q fever went missing. And workers exposed to Q fever, brucellosis or tuberculosis did not realize it until they either became ill or blood tests detected the exposure.


The recent number of mistakes documented at federal laboratories involving anthrax, flu and smallpox viruses have contributed to a debate over lax government oversight at high-level containment labs.

Ban on gain-of-function studies ends

The debate is focused on a subset of gain-of-function studies that manipulate deadly viruses to increase their transmissibility or virulence. “This is what happens to viruses in the wild”, explains Carrie Wolinetz, head of the NIH Office of Science Policy. “Gain-of-function experiments allow us to understand how pandemic viruses evolve, so that we can make predictions, develop countermeasures, and do disease surveillance”. Although none of the widely publicised mishaps of 2014 involved such work, the NIH decided to suspend funding for gain-of-function studies involving influenza, MERS-CoV, and SARS-CoV.


The US moratorium on gain-of-function experiments has been rescinded, but scientists are split over the benefits—and risks—of such studies. Talha Burki reports.

On Dec 19, 2017, the US National Institutes of Health (NIH) announced that they would resume funding gain-of-function experiments involving influenza, Middle East respiratory syndrome coronavirus, and severe acute respiratory syndrome coronavirus. A moratorium had been in place since October, 2014. At the time, the NIH had stated that the moratorium “will be effective until a robust and broad deliberative process is completed that results in the adoption of a new US Government gain-of-function research policy”. This process has now concluded. It was spearheaded by the National Science Advisory Board for Biosecurity (NSABB) and led to the development of a new framework for assessing funding decisions for research involving pathogens with enhanced pandemic potential. The release of the framework by the Department of Health and Human Services (HHS), of which NIH is part, signalled the end of the funding pause.

The situation has its roots in 2011, when the NSABB suppressed two studies involving H5N1 viruses that had been modified to allow airborne transmission from ferret to ferret. They worried that malign actors could replicate the work to deliberately cause an outbreak in human beings. After much debate, the studies were published in full in 2012. HHS subsequently issued guidelines for funding decisions on experiments likely to result in highly pathogenic H5N1 viruses transmissible from mammal to mammal via respiratory droplets. The guidelines were later expanded to include H7N9 viruses.

The Second Study on Vitamin D and COVID-19 Is Now Out

The first study on vitamin D and COVID-19 was released as a preprint on April 23, and a second study was released as a preprint on April 26. Here’s what we can learn from the second study. The first study, which I reported on a few days ago, focused on disease severity, while the second one, which I’m reporting on here, focused on mortality.

The Results

The electronic health records of 780 laboratory-confirmed COVID-19 cases from the government hospitals of Indonesia between March 2 and April 24 was searched for data on vitamin D status prior to admission, age, sex, preexisting conditions, and mortality. Vitamin D status was classified as normal (≥30 ng/mL), insufficient (21−29 ng/mL), or deficient (≤20 ng/mL).

The US already has the technology to test millions of people a day

There is widespread agreement that the only way to safely reopen the economy is through a massive increase in testing. The US needs to test millions of people per day to effectively track and then contain the covid-19 pandemic.

This is a tall order. The country tested only around 210,000 people per day last week, and the pace is not increasing fast enough to get to millions quickly.

The urgency to do better is overwhelmingly bipartisan, with the most recent legislation adding $25 billion for testing a few days ago. Fears are growing, however, that testing might not scale in time to make a difference. As Senators Lamar Alexander and Roy Blunt wrote last week, “We have been talking with experts across the government and the private sector to find anyone who believes that current technology can produce the tens of millions of tests necessary to put this virus behind us. Unfortunately, we have yet to find anyone to do so.”

The US government is helping get cash to private space companies, replacing frozen venture capital

Investment in the fast-growing space industry was booming well into the first quarter of 2020 but private capital has largely frozen as the coronavirus pandemic strikes the U.S., leading both civil and military agencies to step up funding for corporate partners.

“We kicked into high gear as soon as it was apparent a lot of companies were not going to be able to conduct business as usual due to distancing requirements,” Mike Read, International Space Station business and economic development manager at NASA’s Johnson Space Center, told CNBC.

U.S. equity investment in space companies totaled $5.4 billion across 36 deals in the first quarter, according to a report Friday by NYC-based firm Space Capital. But the second quarter is likely to just see a fraction of that investment, according to Space Capital managing partner Chad Anderson, as deal flow in the U.S. will follow China’s path. Chinese investment in space was climbing by record amounts until the first quarter, when “activity in China was basically shut off,” Anderson said.

Smash and Grab – The UK’s Money Laundering Machine

Download the full report here.

In 2017, Bellingcat and Transparency International UK published their joint report, “Offshore in the UK”, describing the phenomenon of Scottish Limited Partnerships (“SLPs”) and their use as a mechanism in global money laundering scandals and a range of illicit activities. Since then, SLPs have continued to be implicated in further scandals, perhaps most notably the Azerbaijani Laundromat, a scheme where $2.9 billion was laundered through UK companies.

In the same year, SLPs became obliged to register their Person of Significant Control at Companies House, and the boom in registrations ended. The government subsequently ran a public consultation into limited partnerships, and published its conclusions in December 2018. Currently, SLP registrations are at their lowest level since 2010. Nevertheless, a lack of regulation allowed thousands of opaquely owned partnerships, typically with no tangible link to the Uk, to flourish over a seven year period. We do not have the details of the business activities of these SLPs, who controlled them, or who their true beneficial owners are.

Sunlight destroys coronavirus quickly, say US scientists

The new coronavirus is quickly destroyed by sunlight, according to new research announced by a senior US official on Thursday, though the study has not yet been made public and awaits external evaluation.

William Bryan, science and technology advisor to the Department of Homeland Security secretary, told reporters at the White House that government scientists had found had a potent impact on the pathogen, offering hope that its spread may ease over the summer.

“Our most striking observation to date is the powerful effect that solar light appears to have on killing the virus, both surfaces and in the air,” he said.

The Open Source Hunt for Syria’s Favourite Sarin Bomb

O,.,o.


Throughout Syria’s lengthy conflict, Bellingcat has worked to investigate a large number of chemical attacks, including the nature of the weapons deployed in those attacks, using open source evidence. From modified chlorine cylinders to locally made surface to surface rockets filled with Sarin, Bellingcat has revealed the nature, and origin, of these chemical weapons, confirming the Syrian government’s involvement in a range of chemical attacks.

Following a series of Sarin attacks in Al Lataminah and Khan Sheikhoun in March and April 2017, Bellingcat worked with open source evidence to slowly piece together the nature of the bomb used in the attacks. Bellingcat first published its conclusions in November 2017, and continued to build on the body of evidence it had uncovered. After the OPCW Investigation and Identification Team (IIT) report was published this week, confirming the type of bomb used in the March 24 and March 30, 2017 Sarin attacks in Al Lataminah, we now have their confirmation of the type of bomb used, the Syrian M4000 chemical bomb.

In this article, we examine the evidence and processes used by Bellingcat to identify this same munition, and what it tells us about the use of Sarin as a chemical weapons in Syria, years after Syria was meant to have destroyed its chemical weapons stockpiles in the aftermath of the August 21, 2013 Sarin attacks.

America’s bomber force is facing a crisis

The path forward begins with admitting the nation has a bomber shortfall. Retiring more aircraft exacerbates the problem. Nor is this just an Air Force problem. Bombers are national assets essential to our security strategy and must be prioritized accordingly. If other services have excess funds to invest in ideas like a 1,000-mile-range cannon when thousands of strike aircraft, various munitions and remotely piloted aircraft can fill the exact same mission requirements, it is time for a roles and missions review to direct funding toward the most effective, efficient options. Bombers would compete well in such an assessment. Ultimately, the solution demands doubling down on the B-21 program.

There comes a point where you cannot do more with less. Given the importance of bombers to the nation, rebuilding the bomber force is not an option — it is an imperative.

Retired U.S. Air Force Maj. Gen. Larry Stutzriem served as a fighter pilot and held various command positions. He concluded his service as the director of plans, policy and strategy at North American Aerospace Defense Command and U.S. Northern Command. He is currently the director of studies at the Mitchell Institute for Aerospace Studies, where Douglas Birkey is the executive director. Birkey researches issues relating to the future of aerospace and national security, and he previously served as the Air Force Association’s director of government relations.

/* */